CalciMedica (CALC) Stock Forecast, Price Target & Predictions


OverviewFinancialsChart

CALC Stock Forecast


CalciMedica stock forecast is as follows: an average price target of $266.00 (represents a 9266.20% upside from CALC’s last price of $2.84) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CALC Price Target


The average price target for CalciMedica (CALC) is $266.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $392.00 to $14.00. This represents a potential 9266.20% upside from CALC's last price of $2.84.

CALC Analyst Ratings


Buy

According to 3 Wall Street analysts, CalciMedica's rating consensus is 'Buy'. The analyst rating breakdown for CALC stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

CalciMedica Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 20, 2024Leland GershallOppenheimer$14.00$5.45156.88%392.96%
Nov 22, 2022Christopher RaymondRaymond James$392.00$146.90166.84%13702.82%
May 18, 2022Christopher RaymondPiper Sandler$392.00$171.81128.15%13702.82%

The latest CalciMedica stock forecast, released on May 20, 2024 by Leland Gershall from Oppenheimer, set a price target of $14.00, which represents a 156.88% increase from the stock price at the time of the forecast ($5.45), and a 392.96% increase from CALC last price ($2.84).

CalciMedica Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$14.00
Last Closing Price$2.84$2.84$2.84
Upside/Downside-100.00%-100.00%392.96%

In the current month, the average price target of CalciMedica stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CalciMedica's last price of $2.84. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 28, 2024OppenheimerOutperformOutperformHold
Jun 28, 2024H.C. WainwrightBuyBuyHold
May 20, 2024OppenheimerOutperformOutperformHold
May 18, 2022Piper SandlerNeutralNeutralHold

CalciMedica's last stock rating was published by Oppenheimer on Jun 28, 2024. The company gave CALC a "Outperform" rating, the same as its previous rate.

CalciMedica Financial Forecast


CalciMedica Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 22
Revenue--------
Avg Forecast$100.00M------$75.00K
High Forecast$100.00M------$75.00K
Low Forecast$100.00M------$75.00K
# Analysts1------1
Surprise %--------

CalciMedica's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CALC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

CalciMedica EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 22
# Analysts1------1
EBITDA-------$-10.06M
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

undefined analysts predict CALC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CalciMedica's previous annual EBITDA (undefined) of $NaN.

CalciMedica Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 22
# Analysts1------1
Net Income-------$-10.15M
Avg Forecast$8.52M$-5.68M$-4.12M$-4.01M$-4.90M$-6.26M$-6.39M$-59.52M
High Forecast$8.52M$-5.68M$-4.12M$-3.05M$-3.67M$-6.26M$-6.39M$-59.52M
Low Forecast$8.52M$-5.68M$-4.12M$-4.97M$-6.12M$-6.26M$-6.39M$-59.52M
Surprise %-------0.17%

CalciMedica's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CALC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

CalciMedica SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 22
# Analysts1------1
SG&A-------$4.13M
Avg Forecast--------
High Forecast--------
Low Forecast--------
Surprise %--------

CalciMedica's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CALC last annual SG&A of $4.13M (Mar 22).

CalciMedica EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 22
# Analysts1------1
EPS-------$-1.81K
Avg Forecast$0.77$-0.51$-0.37$-0.36$-0.44$-0.56$-0.57$-5.35
High Forecast$0.77$-0.51$-0.37$-0.27$-0.33$-0.56$-0.57$-5.35
Low Forecast$0.77$-0.51$-0.37$-0.45$-0.55$-0.56$-0.57$-5.35
Surprise %-------337.79%

According to undefined Wall Street analysts, CalciMedica's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CALC previous annual EPS of $NaN (undefined).

CALC Forecast FAQ


Is CalciMedica a good buy?

Yes, according to 3 Wall Street analysts, CalciMedica (CALC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CALC's total ratings.

What is CALC's price target?

CalciMedica (CALC) average price target is $266 with a range of $14 to $392, implying a 9266.20% from its last price of $2.84. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CalciMedica stock go up soon?

According to Wall Street analysts' prediction for CALC stock, the company can go up by 9266.20% (from the last price of $2.84 to the average price target of $266), up by 13702.82% based on the highest stock price target, and up by 392.96% based on the lowest stock price target.

Can CalciMedica stock reach $4?

CALC's average twelve months analyst stock price target of $266 supports the claim that CalciMedica can reach $4 in the near future.

What are CalciMedica's analysts' financial forecasts?

CalciMedica's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-17.551M (high $-16.326M, low $-18.776M), average SG&A $0 (high $0, low $0), and average EPS is $-1.576 (high $-1.466, low $-1.687). CALC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $100M (high $100M, low $100M), average EBITDA is $0 (high $0, low $0), average net income is $-5.289M (high $-4.327M, low $-6.251M), average SG&A $0 (high $0, low $0), and average EPS is $-0.475 (high $-0.389, low $-0.561).